Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases

Biological Chemistry

Volumn 385, Issue 11, 2004, Pages 1035-1039

  Abdel Rahman, Hamdy M ^a   Kimura, Tooru ^a   Hidaka, Koushi ^a   Kiso, Aiko ^a   Nezami, Azin ^b   Freire, Ernesto ^b   Hayashi, Yoshio ^a   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Allophenylnorstatine; Antiviral activity; HTLV I; Malaria; Protease inhibitors

Indexed keywords

3 AMINO 2 HYDROXY 4 PHENYLBUTYRIC ACID; AMINO ACID; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; CATHEPSIN D; GAG PROTEIN; JE 2147; KNI 10006; KNI 10007; KNI 10026; KNI 10159; KNI 10160; KNI 10161; KNI 10162; KNI 1269; KNI 1689; KNI 727; KNI 764; KNI 840; KYNOSTATIN 272; PLASMEPSIN II; PROTEIN P19; PROTEINASE INHIBITOR; SM 319777; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA; MALARIA; MOLECULAR MIMICRY; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN TARGETING; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ANTIVIRAL AGENTS; ASPARTIC ENDOPEPTIDASES; HIV; HUMAN T-LYMPHOTROPIC VIRUS 1; PLASMODIUM FALCIPARUM; PROTEASE INHIBITORS;

HUMAN T-LYMPHOTROPIC VIRUS 1; PLASMODIUM FALCIPARUM;

EID: 10044264132     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2004.134     Document Type: Short Survey

References (22)

1. Abdel-Rahman, H.M., Al-Karamany, G.S., El-Koussi, N.A., Youssef, A.F., and Kiso, Y. (2002). HIV protease inhibitors: peptidomimetic drugs and future perspectives. Curr. Med. Chem. 9, 1905-1922.
2. Boss, C., Richard-Bildstein, S., Weller, T., Fischli, W., Meyerm S., and Binkert, C. (2003). Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr. Med. Chem. 10, 883-907.
3. Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C., Kay, J., and Mottram, J. (2001). Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17, 532-537.
4. Hamada, Y., and Kiso, Y. (2003). Protease inhibitors: design and new features. Kagaku To Seibutsu 41, 796-803.
5. Kimura, T., Hidaka, K., Abdel-Rahman, H.M., Matsumoto, H., Tanaka, Y., Matsui, Y., Hayashi, Y., and Kiso, Y. (2004). Design and synthesis of dipeptide-type HIV-1 protease inhibitors with high antiviral activity. In: Peptide Science 2003, M. Ueki, ed. (Osaka, Japan: The Japanese Peptide Society), pp. 241-244.
6. Kiso, A., Hidaka, K., Tsuchiya, Y., Kimura, T., Hayashi, Y., Nezami, A., Liu, J., Goldberg, D.E., Freire, E., and Kiso, Y. (2004a). Dipeptide-type inhibitors targeting plasmepsins from Plasmodium faliciparum. In: Peptide Science 2003, M. Ueki, ed. (Osaka, Japan: The Japanese Peptide Society), pp. 235-238.
7. Kiso, A., Hidaka, K., Kimura, T., Hayashi, Y., Nezami, A., Freire, E., and Kiso, Y. (2004b). Search for substrate-based inhibitors fitting the S2′ space of malarial aspartic protease plasmepsin II. J. Peptide Sci., in press.
8. Kiso, Y. (1996). Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 40, 235-244.
9. Kiso, Y., Matsumoto, H., Mizumoto, S., Kimura, T., Fujiwara, Y., and Akaji, K. (1999). Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 51, 59-68.
10. Macchi, B., Balestrieri, E., and Mastino, A. (2003). Effect of nucleoside-based antiretroviral chemotherapy on human T cell leukemia/lymphotropic virus type 1 (HTLV-I) infection in vitro. J. Antimicrob. Chemother. 51, 1327-1330.
11. Maegawa, H., Kimura, T., Arii, Y., Matsui, Y., Hayashi, Y., and Kiso, Y. (2002). Identification of peptidomimetic HTLV-I protease inhibitors containing allophenylnorstatine as a transition-state isostere. In: Peptides 2002, E. Benedetti and C. Pedone, eds. (Naples, Italy: Edizioni Ziino), pp. 548-549.
12. Maegawa, H., Kimura, T., Arii, Y., Matsui, Y., Kasai, S., Hayashi, Y., and Kiso, Y. (2004). Identification of peptidomimetic HTLV-I protease inhibitors containing allophenylnorstatine as the transition-state mimic. Bioorg. Med. Chem. Lett., in press.
13. Mimoto, T., Kato, R., Takaku, H., Nojima, S., Terashima, K., Misawa, S., Kukazawa, T., Ueno, T., Sato, H., Shintani, M., Kiso, Y., and Hayashi, H. (1999). Structure-activity relationship on small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 42 1789-1802.
14. Mimoto, T., Terashima, K., Nojima, S., Takaku, H., Nakayama, M., Shintani, M., Yamaoka, T., and Hayashi, H. (2004). Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure. Bioorg. Med. Chem. 12, 281-293.
15. Nezami, A., Laque, I., Kimura, T., Kiso, Y., and Freire, E. (2002). Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry 41 2273-2280.
16. Nezami, A., Kimura, T., Hidaka, K., Kiso., A., Liu, J., Kiso, Y., Goldberg, D.E., and Freire, E. (2003). High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42, 8459-8464.
17. Reiling, K.K., Endres, N.F., Dauber, D.S., Craik, C.S., and Stroud, R.M. (2002). Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 Å structure. Biochemistry 41, 4582-4594.
18. Shuker, S.B., Mariani, V.L., Herger, B.E., and Danisson, K.J. (2003). Understanding HTLV-I protease. Chem. Biol. 10, 373-380.
19. UNAIDS and World Health Organization Report (2003). http://www.unaids.org.
20. Vega, S., Kang, L.-W., Velazquez-Campoy, A., Kiso, Y., Amzel, L.M., and Freire, E. (2004). A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins Struct. Funct. Bioinformatics 55, 594-602.
21. Velazquez-Campoy, A., Kiso, Y., and Freire, E. (2001). The binding energetics of first and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390 169-175.
22. Yoshimura, K., Kato, R., Yusa, K., Kavlick, M.F., Maroun, V., Nguyen, A., Mimoto, T., Ueno, T., Shintani, M., Falloon, J., et al. (1999). JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. USA 96, 8675-8680.